TY - JOUR
T1 - Prognostic impact of complex karyotype on post-transplant outcomes of myelofibrosis
AU - Okada, Yosuke
AU - Takenaka, Katsuto
AU - Murata, Makoto
AU - Shimazu, Yutaka
AU - Tachibana, Takayoshi
AU - Ozawa, Yukiyasu
AU - Uchida, Naoyuki
AU - Wakayama, Toshio
AU - Doki, Noriko
AU - Sugio, Yasuhiro
AU - Tanaka, Masatsugu
AU - Masuko, Masayoshi
AU - Kobayashi, Hikaru
AU - Ino, Kazuko
AU - Ishikawa, Jun
AU - Nakamae, Hirohisa
AU - Matsuoka, Ken ichi
AU - Kanda, Yoshinobu
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Nagamura-Inoue, Tokiko
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Chromosomal abnormalities in the role of prognostic factor for transplant patients with myelofibrosis (MF) are not fully investigated. Regarding complex karyotype (CK), we retrospectively analyzed 241 patients with primary and secondary MF who received a first allogeneic hematopoietic cell transplantation (HCT). Based on an unfavorable karyotype in the Dynamic International Prognostic Scoring System, we compared the outcomes in 3 groups: favorable karyotype, unfavorable karyotype including CK (unfavorable-CK(+)), and unfavorable karyotype not including CK (unfavorable-CK(–)). Overall survival was significantly shorter in the unfavorable-CK(+) group (hazard ratio (HR) 2.49, 95% CI: 1.46–4.24, P < 0.001), whereas there was no difference between the unfavorable-CK(–) group and the favorable group (HR 0.57, 95% CI: 0.20–1.59, P = 0.28). In addition, a significantly higher proportion of patients in the unfavorable-CK(+) group did not achieve complete remission after HCT (P = 0.007). The cumulative incidence of disease progression was significantly higher in the unfavorable-CK(+) group (HR 2.5, 95% CI 1.6–3.92, P < 0.001), whereas that in the unfavorable-CK(–) group was comparable to that in the favorable group (HR 0.49, 95% CI 0.12–1.94, P = 0.31). Further investigations will be needed to clarify the impact of CK on transplant outcomes in MF.
AB - Chromosomal abnormalities in the role of prognostic factor for transplant patients with myelofibrosis (MF) are not fully investigated. Regarding complex karyotype (CK), we retrospectively analyzed 241 patients with primary and secondary MF who received a first allogeneic hematopoietic cell transplantation (HCT). Based on an unfavorable karyotype in the Dynamic International Prognostic Scoring System, we compared the outcomes in 3 groups: favorable karyotype, unfavorable karyotype including CK (unfavorable-CK(+)), and unfavorable karyotype not including CK (unfavorable-CK(–)). Overall survival was significantly shorter in the unfavorable-CK(+) group (hazard ratio (HR) 2.49, 95% CI: 1.46–4.24, P < 0.001), whereas there was no difference between the unfavorable-CK(–) group and the favorable group (HR 0.57, 95% CI: 0.20–1.59, P = 0.28). In addition, a significantly higher proportion of patients in the unfavorable-CK(+) group did not achieve complete remission after HCT (P = 0.007). The cumulative incidence of disease progression was significantly higher in the unfavorable-CK(+) group (HR 2.5, 95% CI 1.6–3.92, P < 0.001), whereas that in the unfavorable-CK(–) group was comparable to that in the favorable group (HR 0.49, 95% CI 0.12–1.94, P = 0.31). Further investigations will be needed to clarify the impact of CK on transplant outcomes in MF.
KW - complex karyotype
KW - hematopoietic cell transplantation
KW - myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=85136505146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136505146&partnerID=8YFLogxK
U2 - 10.1002/hon.3058
DO - 10.1002/hon.3058
M3 - Article
C2 - 35964301
AN - SCOPUS:85136505146
SN - 0278-0232
JO - Hematological Oncology
JF - Hematological Oncology
ER -